Boston Scientific has shared efficacy data for its Farapulse pulsed-field ablation (PFA), recording 65% efficacy for the system at one year in patients with persistent atrial fibrillation (AF).
Boston’s BEAT PERS-AF study (NCT05418725) set out to demonstrate the effectiveness, safety, and procedural efficiency of Farapulse, using the treatment in conjunction with the FARAWAVE PFA catheter, in patients with drug-resistant symptomatic persistent AF.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The data was shared during a late-breaking presentation at the 2026 European Heart Rhythm Association (EHRA) congress, which took place between 12 and 14 April in Paris, France.
Farapulse met the trial’s primary endpoint of effectiveness at 65% among the 49-patient cohort randomised to receive Farapulse treatment, compared to 55% in the 34 patients who received radiofrequency (RF) in the comparator arm.
Effectiveness was defined as freedom from atrial arrhythmia recurrence lasting more than 30 seconds, as detected by rhythm monitoring, along with the absence of cardioversion or resumption of antiarrhythmic drug therapy.
No serious adverse events (SAEs) were observed in the Farapulse arm, while pulmonary vein (PV) stenosis was observed in 12% of patients in the RF comparator arm.
“The BEAT PERS-AF study builds on the safety and efficacy profile of the Farapulse PFA platform in treating patients with persistent atrial fibrillation. These findings are consistent with prior studies and contribute to the growing body of clinical evidence supporting Farapulse,” said Angelo Auricchio, Boston’s chief medical officer for Rhythm Management Europe, Middle East and Africa (EMEA).
Johnson and Johnson (J&J) also presented data at EHRA, sharing interim 12-month results from VARIPURE, a sub-study of its ongoing SECURE (NCT04750798) study, assessing the effectiveness and safety of its Varipulse PFA system in first-time users.
At 12 months, the study reported 84.2% of patients experienced freedom from all documented atrial arrhythmia recurrence, with 90.5% for those with paroxysmal atrial fibrillation (AFib) and 75.3% for persistent cases.
The global electrophysiology ablation catheter market, of which PFA is a part, is on a rapid growth course. According to GlobalData analysis, the market is projected to reach a valuation of $17.6bn in 2035, up from $6.1bn in 2025.
